Welcome to our dedicated page for Innovative Indus SEC filings (Ticker: IIPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Innovative Industrial Properties, Inc. (IIPR) provide detailed insight into how the company describes its business as a real estate investment trust (REIT) focused on specialized industrial and life science real estate. Through Forms 8-K and other reports, the company discloses material events such as financial results, major investments, new credit facilities and changes in its capital structure.
In its current reports on Form 8-K, Innovative Industrial Properties outlines key transactions, including the Securities Purchase Agreement and related documents governing its preferred stock and revolving credit facility investments in IQHQ, Inc., a life science real estate platform. These filings summarize the terms of preferred stock, cumulative dividend rights, warrant coverage, redemption provisions and governance rights, as well as the structure and collateral of related loan agreements.
Other filings describe loan agreements and revolving credit facilities entered into by IIP Operating Partnership, LP and subsidiaries, including borrowing limits, borrowing base formulas, collateral packages and financial covenants such as liquidity and debt service coverage ratios. The company also files 8-Ks to furnish press releases that report quarterly financial results, rental revenues, net income attributable to common stockholders, AFFO, normalized FFO and dividend declarations.
On Stock Titan’s SEC filings page for IIPR, users can access these documents as they are made available through EDGAR, and use AI-powered summaries to understand complex provisions. Filings related to dividends, preferred stock terms, revolving credit facilities, tenant matters and strategic investments help investors analyze how Innovative Industrial Properties finances its portfolio, manages risk and pursues growth in cannabis-focused industrial properties and life science real estate.
IIPR’s Q2-25 results show weakening fundamentals amid tenant stress. Rental revenue fell 21% YoY to $62.9 m as PharmaCann and other operators struggled, driving net income down 38% to $26.0 m and diluted EPS to $0.86 (vs $1.44).
Cash flow from operations remained positive at $102.7 m but slipped 24% YoY; cash on hand dropped to $99.7 m after funding $22.9 m of investments, repurchasing $20.1 m of common stock and paying $108.7 m in common dividends ($1.90/sh each quarter). Dividends now exceed cumulative earnings, pushing “dividends in excess of earnings” to –$264 m.
Balance-sheet leverage is modest (liabilities $425 m vs equity $1.88 b), yet the $291 m 5.5% notes maturing May 2026 loom large. Management admits current liquidity is insufficient and intends to refinance, assuming access to capital markets.
Tenant concentration remains high: top five operators generated 49% of rental revenue; PharmaCann defaulted in March, nullifying rent concessions, while two leases shifted to sales-type accounting with cash payments booked as deposits. An impairment of $3.5 m was recorded in Q1 and one California asset was sold for $1.8 m at book value.
The company issued 559 k Series A preferred shares via its ATM for $13.2 m and increased preferred outstanding to 1.56 m shares; early bond repayments of $8.8 m trimmed debt. Multiple securities-law class actions remain pending.